FEB 12 1996



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Thomas D. Hoffman Schering-Plough Corporation Patent Department (K-6-1 - 1990) 2000 Galloping Hill Road Kenilworth, NJ 07033-0540

Patent Term Extension Application for U.S. Patent No. 4,470,972

## NOTICE OF FINAL DETERMINATION

Re:

A determination has been made that U.S. Patent No. 4,470,972, which claims the human drug product RENORMAX, is eligible for patent term extension under 35 U.S.C. § 156. The period of extension has been determined to be <u>two years</u>.

The period of extension has been calculated using the FDA determination of the length of the regulatory review period published in the Federal Register of July 14, 1995 (60 Fed. Reg. 36,291). Under 35 U.S.C. § 156(c):

Period of Extension = 1/2 (Testing Phase) + Approval Phase

= 1/2 (2,901 - 233) + 1,095

= 2,429 days

Since the regulatory review period began January 22, 1984, before the patent issued (September 11, 1984), only that portion of the regulatory review period occurring after the date the patent issued has been considered in the above determination of the length of the extension period 35 U.S.C. § 156(c). (From January 22, 1984 to September 11, 1984 is 233 days; this period is subtracted for the number of days occurring in the testing phase according to the FDA determination of the length of the regulatory review period: (2,901 - 233 = 2,768 days.) No determination of a lack of due diligence under 35 U.S.C. § 156(c)(1) was made.

The two year limitation of 35 U.S.C. § 156(g)(6)(C) applies in the present situation because: (1) the patent was issued before the date of enactment (September 24, 1984) of 35 U.S.C. § 156; (2) the date of exemption under subsection 505(i) of the Federal Food, Drug and Cosmetic Act involving the approved product became effective (January 22, 1984) was before the date of enactment; and, (3) the date of the new drug application was approved (December 29, 1994) was after the date of enactment. Since the period of extension calculated under 35 U.S.C. § 156(c) for the patent cannot exceed two years under 35 U.S.C. § 156(g)(6)(C), the period of extension will be for two years.

The 14 year limitation of 35 U.S.C. § 156(c)(3) does not operate to further reduce the period of extension determined above.

A single request for reconsideration of this final determination as to the length of extension of the term of the patent may be made if filed within <u>one month</u> of the date of this notice. Extensions of time under 37 CFR § 1.136(a) are not applicable to this time period. In the absence of such request for reconsideration, the Commissioner will issue a certificate of extension, under seal, for a period of two years.

Upon issuance of the certificate of extension, the following information will be published in the Official Gazette:

U.S. Patent No.:

4,470,972

Granted:

September 11, 1984

Applicant:

Elijah H. Gold, et al.

Owner of Record:

**Schering Corporation** 

Title:

7-CARBOXYALKYLAMINOACYL-1,4-

DITHIA-7-AZASPIRO[4,4]-NONANE-8-CAR-

**BOXYLIC ACIDS** 

Classification:

514/19

Product Trade Name:

RENORMAX

Term Extended:

TWO YEARS

Hiram A. Bernstein

Senior Legal Advisor

Special Program Law Office

Office of the Deputy Assistant Commissioner

for Patent Policy and Projects

(703) 305-9285

cc:

Ronald L. Wilson, Director Health Assessment Policy Staff Office of Health Affairs (HFY-20) Food and Drug Administration 5600 Fishers Lane, Room 11-44 Rockville, MD 20857 RE: RENORMAX

FDA Docket No.: 95E-0076